NCT00749788View on ClinicalTrials.gov

Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Dyslipidemia
Interventions
DRUG

JTT-302

JTT-302, 100 mg tablets, 200 mg dose, oral, 30 minutes after the start of the morning meal

DRUG

JTT-302

JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal

DRUG

Placebo

Matching placebo tablets, oral, 30 minutes after the start of the morning meal

Trial Locations (1)

Unknown

Santa Ana

Sponsors

Lead Sponsor

Akros Pharma Inc.
All Listed Sponsors
lead

Akros Pharma Inc.

INDUSTRY

NCT00749788 - Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels | Biotech Hunter | Biotech Hunter